Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2009 by Govind Ballabh Pant Hospital.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
Govind Ballabh Pant Hospital
ClinicalTrials.gov Identifier:
NCT01175538
First received: August 2, 2010
Last updated: August 4, 2010
Last verified: October 2009

August 2, 2010
August 4, 2010
January 2008
June 2010   (final data collection date for primary outcome measure)
prevention of first episode of hepatic encephalopathy [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Same as current
No Changes Posted
Side effects to lactulose and mortality [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis
Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose
To assess the effects of lactulose for the prevention of first episode of altered sensorium (hepatic encephalopathy, primary prophylaxis) in patients with cirrhosis.
Development of hepatic encephalopathy in a patient with cirrhosis is associated with poor survival rate of 10-70% at one year depending upon hepatic and renal functions. Treating patients to prevent development of first episode of hepatic encephalopathy is classified as primary prophylaxis of hepatic encephalopathy and preventing recurrence of hepatic encephalopathy in patients who had previous episode of hepatic encephalopathy is secondary prophylaxis of hepatic encephalopathy
Interventional
Phase 4
Primary Purpose: Treatment
Hepatic Encephalopathy
  • Drug: Lactulose
    In the Gp-L group, patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day
  • Drug: Lactulose
    lactulose will be used in 30-60ml/day
Experimental: Lactulose
Interventions:
  • Drug: Lactulose
  • Drug: Lactulose
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
Not Provided
September 2010
June 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • cirrhotic patients(18-70yrs) who never had encephalopathy

Exclusion Criteria:

  • history of taking lactulose in the past 6 weeks
  • alcohol intake during the past 6 weeks
  • hepatocellular carcinoma
  • previous TIPS or shunt surgery
  • significant co morbid illness such as heart, respiratory, or renal failure
  • neurologic diseases such as alzheimer's disease, parkinson's disease and nonhepatic metabolic encephalopathies.
  • patients on psychoactive drugs such as antidepressants or sedatives
  • who restarted alcohol during follow up
Both
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
India
 
NCT01175538
PS001
Yes
Not Provided
Not Provided
Prof Barjesh Chander Sharma, G B Pant Hospital
Govind Ballabh Pant Hospital
Not Provided
Principal Investigator: Barjesh C Sharma, MD,DM G B Pant Hospital New Delhi 110002
Govind Ballabh Pant Hospital
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP